Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance
Open Access
- 22 November 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Abstract
Most cancers are resistant to anti-PD-1/PD-L1 and chemotherapy. Herein we identify PDLIM2 as a tumor suppressor particularly important for lung cancer therapeutic responses. While PDLIM2 is epigenetically repressed in human lung cancer, associating with therapeutic resistance and poor prognosis, its global or lung epithelial-specific deletion in mice causes increased lung cancer development, chemoresistance, and complete resistance to anti-PD-1 and epigenetic drugs. PDLIM2 epigenetic restoration or ectopic expression shows antitumor activity, and synergizes with anti-PD-1, notably, with chemotherapy for complete remission of most lung cancers. Mechanistically, through repressing NF-κB/RelA and STAT3, PDLIM2 increases expression of genes involved in antigen presentation and T-cell activation while repressing multidrug resistance genes and cancer-related genes, thereby rendering cancer cells vulnerable to immune attacks and therapies. We identify PDLIM2-independent PD-L1 induction by chemotherapeutic and epigenetic drugs as another mechanism for their synergy with anti-PD-1. These findings establish a rationale to use combination therapies for cancer treatment.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA172090)
- American Lung Association (LCD 259111-N)
- American Cancer Society (PF-12-081-01-TBG)
This publication has 63 references indexed in Scilit:
- Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinomaProceedings of the National Academy of Sciences, 2012
- Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesisOncogene, 2010
- Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung TumorigenesisCancer Research, 2010
- Epigenetic Repression of PDZ-LIM Domain-containing Protein 2Journal of Biological Chemistry, 2010
- DNA Methylation–Dependent Repression of PDZ-LIM Domain–Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic TargetCancer Research, 2010
- Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growthNature Medicine, 2010
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinomaNature, 2009
- Endoproteolytic processing of C-terminally truncated NF-κB2 precursors at κB-containing promotersProceedings of the National Academy of Sciences, 2007
- Common markers of proliferationNature Reviews Cancer, 2006
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999